# New York Blood Center, Inc. – FDA 483, Jul 17, 2026

Source: https://www.keypedia.com/records/483/new-york-blood-center-inc/e31a0a8e-f30f-4ff1-a2fd-e45849d6c173

> FDA 483 for New York Blood Center, Inc. on July 17, 2026. Product: biologics. Access full analysis and detailed observations.

---

## Details

- Record Type: 483
- Company Name: New York Blood Center, Inc.
- Inspection Date: 2026-07-17
- Product Type: biologics
- Office Name: New York District Office
- Summary: The FDA inspected New York Blood Center, Inc. in New York, NY, a donor center, and identified three observations. The inspection revealed deficiencies in following written standard operating procedures for blood collection, a failure to make written procedures available to personnel, and inadequate record-keeping that did not always identify the person performing work or provide a complete history of apheresis collections. These issues indicate a need for improved adherence to established protocols and documentation practices.

## Related Officers

- [Investigator](https://www.keypedia.com/people/irina-gaberman/c863b2de-4c64-40d2-a390-289d293e5a8f)

Company: https://www.keypedia.com/companies/new-york-blood-center-inc/ea0e2960-d3d1-4b67-b67b-d1824e9f6778

Office: https://www.keypedia.com/offices/new-york-district-office/9fa3d265-16ca-438d-8a6e-b47f60dc260d